Meet the Start-ups
Nazma Ilahibaks | CEO & Co-founder | JAMA Therapeutics
Dr. Nazma Ilahibaks is CEO and co-founder of JAMA Tx, solving one of the hardest problem in genetic medicine for heart patients — delivery. JAMA Tx is developing a new platform enabling multimodality delivery of RNA, protein, and programmable gene editors into heart tissue for treating cardiogenetic diseases. As platform co-inventor, she has secured over €1.3M in competitive funding to drive preclinical validation with a dedicated team.
In earlier business development roles, she closed 20 contracts worth over €2.0M with leading pharma and medtech partners within 12 months, and managed a €6.3M R&D portfolio in interventional cardiology. Additionally, she supported the creation of new cardiovascular and regenerative medicine ventures from academia in the Netherlands through the DCVA/RegMed XB Thematic Technology Transfer program.
She has 8+ years of experience developing non-viral delivery systems for cardiovascular disease applications and holds a PhD in Regenerative Medicine from Utrecht University.
About JAMA Therapeutics
JAMA Tx is fixing the part of genetic medicine that keeps failing patients — getting treatments into the heart. We build tiny, cell-made carriers for safely and precisely delivering therapeutic RNA, proteins, and programmable gene editors to heart cells. The aim is simple: More medicine where it is needed, less where it is not, and a cleaner safety and efficacy profile than today’s delivery options. Spun out of UMC Utrecht with €1.3M in competitive funding, we are advancing a platform to treat inherited heart diseases where current gene therapies still fall short.
Sponsors 2026
| Powered by: Hyphen Projects | Connect | Join Global Investor Forum | |||
| Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
|
REGISTER NOW
SUBSCRIBE TO OUR NEWSLETTER
|
© Copyright 2025 by Hyphen Projects